Spero Therapeutics (NASDAQ:SPRO – Get Rating) announced its quarterly earnings data on Monday. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.14), MarketWatch Earnings reports. Spero Therapeutics had a negative net margin of 491.65% and a negative return on equity of 87.72%. During the same period in the […]